Zura Bio

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates as operating losses widened to $29.3M versus the $24.7M expected. Diluted GAAP EPS of -$0.21 missed the -$0.19 mean estimate, primarily driven by a 138% YoY surge in R&D expenses to $20.7M as Phase 2 clinical trials for tibulizumab (ZB-106) accelerated. Despite the earnings miss, the company maintains a robust liquidity position with $205.1M in cash, providing a projected operational runway through the end of 2028.